JP2007500700A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007500700A5 JP2007500700A5 JP2006521933A JP2006521933A JP2007500700A5 JP 2007500700 A5 JP2007500700 A5 JP 2007500700A5 JP 2006521933 A JP2006521933 A JP 2006521933A JP 2006521933 A JP2006521933 A JP 2006521933A JP 2007500700 A5 JP2007500700 A5 JP 2007500700A5
- Authority
- JP
- Japan
- Prior art keywords
- indazol
- propenamide
- prop
- amino
- enoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 10
- -1 1H-indazol-3-yl Chemical group 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 239000005711 Benzoic acid Substances 0.000 claims 2
- 125000000732 arylene group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 235000010233 benzoic acid Nutrition 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000005549 heteroarylene group Chemical group 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- UJFIXTDBQVZLOI-ZHACJKMWSA-N (e)-1-(4-benzylpiperidin-1-yl)-3-(1h-indazol-3-yl)prop-2-en-1-one Chemical compound N=1NC2=CC=CC=C2C=1/C=C/C(=O)N(CC1)CCC1CC1=CC=CC=C1 UJFIXTDBQVZLOI-ZHACJKMWSA-N 0.000 claims 1
- PQKCLCOVJGRGEI-AATRIKPKSA-N (e)-3-(1h-indazol-3-yl)-1-(4-pyrazin-2-ylpiperazin-1-yl)prop-2-en-1-one Chemical compound N=1NC2=CC=CC=C2C=1/C=C/C(=O)N(CC1)CCN1C1=CN=CC=N1 PQKCLCOVJGRGEI-AATRIKPKSA-N 0.000 claims 1
- NBRMWBYRKNYPOP-BQYQJAHWSA-N (e)-3-(1h-indazol-3-yl)-n-(2-methylpropyl)prop-2-enamide Chemical compound C1=CC=C2C(/C=C/C(=O)NCC(C)C)=NNC2=C1 NBRMWBYRKNYPOP-BQYQJAHWSA-N 0.000 claims 1
- PTIDBCQCYIWPJT-CMDGGOBGSA-N (e)-3-(1h-indazol-3-yl)-n-(3,4,5-trimethoxyphenyl)prop-2-enamide Chemical compound COC1=C(OC)C(OC)=CC(NC(=O)\C=C\C=2C3=CC=CC=C3NN=2)=C1 PTIDBCQCYIWPJT-CMDGGOBGSA-N 0.000 claims 1
- ZDOKWVCTYKDDIZ-BQYQJAHWSA-N (e)-3-(1h-indazol-3-yl)-n-(6-methoxypyridin-3-yl)prop-2-enamide Chemical compound C1=NC(OC)=CC=C1NC(=O)\C=C\C1=NNC2=CC=CC=C12 ZDOKWVCTYKDDIZ-BQYQJAHWSA-N 0.000 claims 1
- ZOXOITLUYSGMGB-VQHVLOKHSA-N (e)-3-(1h-indazol-3-yl)-n-[3-methoxy-4-(2-morpholin-4-ylethoxy)phenyl]prop-2-enamide Chemical compound COC1=CC(NC(=O)\C=C\C=2C3=CC=CC=C3NN=2)=CC=C1OCCN1CCOCC1 ZOXOITLUYSGMGB-VQHVLOKHSA-N 0.000 claims 1
- BQQPHEGUYHFUGX-CSKARUKUSA-N (e)-3-(1h-indazol-3-yl)-n-[3-methoxy-4-[2-(2-methoxyethylamino)ethoxy]phenyl]prop-2-enamide Chemical compound C1=C(OC)C(OCCNCCOC)=CC=C1NC(=O)\C=C\C1=NNC2=CC=CC=C12 BQQPHEGUYHFUGX-CSKARUKUSA-N 0.000 claims 1
- XDSQLYIXWGORNM-WYMLVPIESA-N (e)-3-(1h-indazol-3-yl)-n-[3-methoxy-4-[2-(2-phenoxyethylamino)ethoxy]phenyl]prop-2-enamide Chemical compound COC1=CC(NC(=O)\C=C\C=2C3=CC=CC=C3NN=2)=CC=C1OCCNCCOC1=CC=CC=C1 XDSQLYIXWGORNM-WYMLVPIESA-N 0.000 claims 1
- DRASAARUWQATHR-ZRDIBKRKSA-N (e)-3-(1h-indazol-3-yl)-n-[3-methoxy-4-[2-[methyl(propyl)amino]ethoxy]phenyl]prop-2-enamide Chemical compound C1=C(OC)C(OCCN(C)CCC)=CC=C1NC(=O)\C=C\C1=NNC2=CC=CC=C12 DRASAARUWQATHR-ZRDIBKRKSA-N 0.000 claims 1
- RFMTWNVTCAHWSS-ZHACJKMWSA-N (e)-3-(1h-indazol-3-yl)-n-quinolin-5-ylprop-2-enamide Chemical compound C1=CC=C2C(/C=C/C(NC=3C4=CC=CN=C4C=CC=3)=O)=NNC2=C1 RFMTWNVTCAHWSS-ZHACJKMWSA-N 0.000 claims 1
- CCNBMODZORJIGI-BQYQJAHWSA-N (e)-n-(1,3-benzothiazol-6-yl)-3-(1h-indazol-3-yl)prop-2-enamide Chemical compound C1=CC=C2C(/C=C/C(NC=3C=C4SC=NC4=CC=3)=O)=NNC2=C1 CCNBMODZORJIGI-BQYQJAHWSA-N 0.000 claims 1
- JXMYVBPMGBOBCY-ZHACJKMWSA-N (e)-n-(2,3-dihydro-1h-inden-5-yl)-3-(1h-indazol-3-yl)prop-2-enamide Chemical compound C1=CC=C2C(/C=C/C(NC=3C=C4CCCC4=CC=3)=O)=NNC2=C1 JXMYVBPMGBOBCY-ZHACJKMWSA-N 0.000 claims 1
- GKJUBVWJSMCBNT-MDZDMXLPSA-N (e)-n-(2-cyanophenyl)-3-(1h-indazol-3-yl)prop-2-enamide Chemical compound N=1NC2=CC=CC=C2C=1/C=C/C(=O)NC1=CC=CC=C1C#N GKJUBVWJSMCBNT-MDZDMXLPSA-N 0.000 claims 1
- OAOQRAYQACNNII-BQYQJAHWSA-N (e)-n-(3,4-dimethyl-1,2-oxazol-5-yl)-3-(1h-indazol-3-yl)prop-2-enamide Chemical compound CC1=NOC(NC(=O)\C=C\C=2C3=CC=CC=C3NN=2)=C1C OAOQRAYQACNNII-BQYQJAHWSA-N 0.000 claims 1
- JHRAGLLNHTUVQV-MDZDMXLPSA-N (e)-n-(3-acetamidophenyl)-3-(1h-indazol-3-yl)prop-2-enamide Chemical compound CC(=O)NC1=CC=CC(NC(=O)\C=C\C=2C3=CC=CC=C3NN=2)=C1 JHRAGLLNHTUVQV-MDZDMXLPSA-N 0.000 claims 1
- DKXJTYCZBHJPPE-BUHFOSPRSA-N (e)-n-(3-benzoylphenyl)-3-(1h-indazol-3-yl)prop-2-enamide Chemical compound N=1NC2=CC=CC=C2C=1/C=C/C(=O)NC(C=1)=CC=CC=1C(=O)C1=CC=CC=C1 DKXJTYCZBHJPPE-BUHFOSPRSA-N 0.000 claims 1
- VPNUWTCWNUJLCA-SOFGYWHQSA-N (e)-n-(3-chloro-4-morpholin-4-ylphenyl)-3-(1h-indazol-3-yl)prop-2-enamide Chemical compound ClC1=CC(NC(=O)\C=C\C=2C3=CC=CC=C3NN=2)=CC=C1N1CCOCC1 VPNUWTCWNUJLCA-SOFGYWHQSA-N 0.000 claims 1
- LZGXLSAUWCEBNP-CMDGGOBGSA-N (e)-n-(3-chlorophenyl)-3-(1h-indazol-3-yl)prop-2-enamide Chemical compound ClC1=CC=CC(NC(=O)\C=C\C=2C3=CC=CC=C3NN=2)=C1 LZGXLSAUWCEBNP-CMDGGOBGSA-N 0.000 claims 1
- ZDUBHWYWPVXMNY-CMDGGOBGSA-N (e)-n-(5-cyclopropyl-2-methylpyrazol-3-yl)-3-(1h-indazol-3-yl)prop-2-enamide Chemical compound C1=C(NC(=O)\C=C\C=2C3=CC=CC=C3NN=2)N(C)N=C1C1CC1 ZDUBHWYWPVXMNY-CMDGGOBGSA-N 0.000 claims 1
- LNRDAZWJQZRGTJ-BUHFOSPRSA-N (e)-n-[3-(4-benzylpiperazine-1-carbonyl)phenyl]-3-(1h-indazol-3-yl)prop-2-enamide Chemical compound N=1NC2=CC=CC=C2C=1/C=C/C(=O)NC(C=1)=CC=CC=1C(=O)N(CC1)CCN1CC1=CC=CC=C1 LNRDAZWJQZRGTJ-BUHFOSPRSA-N 0.000 claims 1
- QDZSUIBNZJDUIO-VAWYXSNFSA-N (e)-n-[4-(dimethylamino)phenyl]-3-(1h-indazol-3-yl)prop-2-enamide Chemical compound C1=CC(N(C)C)=CC=C1NC(=O)\C=C\C1=NNC2=CC=CC=C12 QDZSUIBNZJDUIO-VAWYXSNFSA-N 0.000 claims 1
- XCBCALVDYASWHD-CSKARUKUSA-N (e)-n-[4-[2-(4-acetylpiperazin-1-yl)ethoxy]-3-methoxyphenyl]-3-(1h-indazol-3-yl)prop-2-enamide Chemical compound COC1=CC(NC(=O)\C=C\C=2C3=CC=CC=C3NN=2)=CC=C1OCCN1CCN(C(C)=O)CC1 XCBCALVDYASWHD-CSKARUKUSA-N 0.000 claims 1
- KERQAMZZSOSVKC-ACCUITESSA-N (e)-n-[4-[2-[2-(4-chlorophenyl)ethylamino]ethoxy]-3-methoxyphenyl]-3-(1h-indazol-3-yl)prop-2-enamide Chemical compound COC1=CC(NC(=O)\C=C\C=2C3=CC=CC=C3NN=2)=CC=C1OCCNCCC1=CC=C(Cl)C=C1 KERQAMZZSOSVKC-ACCUITESSA-N 0.000 claims 1
- OLRPPNBPIIOXPJ-ACCUITESSA-N (e)-n-[4-[2-[di(propan-2-yl)amino]ethoxy]-3-methoxyphenyl]-3-(1h-indazol-3-yl)prop-2-enamide Chemical compound C1=C(OCCN(C(C)C)C(C)C)C(OC)=CC(NC(=O)\C=C\C=2C3=CC=CC=C3NN=2)=C1 OLRPPNBPIIOXPJ-ACCUITESSA-N 0.000 claims 1
- YBHJVZSUKKHPSA-ACCUITESSA-N (e)-n-[5-(diethylsulfamoyl)-2-methoxyphenyl]-3-(1h-indazol-3-yl)prop-2-enamide Chemical compound CCN(CC)S(=O)(=O)C1=CC=C(OC)C(NC(=O)\C=C\C=2C3=CC=CC=C3NN=2)=C1 YBHJVZSUKKHPSA-ACCUITESSA-N 0.000 claims 1
- CVJXCMJIXQTKPH-ZHACJKMWSA-N 8-[(e)-3-(1h-indazol-3-yl)prop-2-enoyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound N=1NC2=CC=CC=C2C=1/C=C/C(=O)N(CC1)CCC1(C(NC1)=O)N1C1=CC=CC=C1 CVJXCMJIXQTKPH-ZHACJKMWSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 101150082971 Sgk1 gene Proteins 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- VRZSASOIMVAPEE-BQYQJAHWSA-N ethyl 1-[(e)-3-(1h-indazol-3-yl)prop-2-enoyl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C(=O)\C=C\C1=NNC2=CC=CC=C12 VRZSASOIMVAPEE-BQYQJAHWSA-N 0.000 claims 1
- CKXNSRXGWGIMBK-PKNBQFBNSA-N ethyl 4-[2-[4-[[(e)-3-(1h-indazol-3-yl)prop-2-enoyl]amino]-2-methoxyphenoxy]ethylamino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NCCOC(C(=C1)OC)=CC=C1NC(=O)\C=C\C1=NNC2=CC=CC=C12 CKXNSRXGWGIMBK-PKNBQFBNSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 150000002431 hydrogen Chemical group 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- PSJWRNJVSMCGMZ-ZHACJKMWSA-N methyl 4-[[(e)-3-(1h-indazol-3-yl)prop-2-enoyl]amino]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1NC(=O)\C=C\C1=NNC2=CC=CC=C12 PSJWRNJVSMCGMZ-ZHACJKMWSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- ONPWQBRKNMHCCG-ZHACJKMWSA-N n-ethyl-3-[[(e)-3-(1h-indazol-3-yl)prop-2-enoyl]amino]-n-(pyridin-4-ylmethyl)benzamide Chemical compound C=1C=CC(NC(=O)\C=C\C=2C3=CC=CC=C3NN=2)=CC=1C(=O)N(CC)CC1=CC=NC=C1 ONPWQBRKNMHCCG-ZHACJKMWSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49082803P | 2003-07-29 | 2003-07-29 | |
| PCT/US2004/023680 WO2005011681A1 (en) | 2003-07-29 | 2004-07-23 | Chemical compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007500700A JP2007500700A (ja) | 2007-01-18 |
| JP2007500700A5 true JP2007500700A5 (https=) | 2007-09-06 |
Family
ID=34115438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006521933A Pending JP2007500700A (ja) | 2003-07-29 | 2004-07-23 | 化合物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20080058515A1 (https=) |
| EP (1) | EP1648448A4 (https=) |
| JP (1) | JP2007500700A (https=) |
| WO (1) | WO2005011681A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004028862A1 (de) | 2004-06-15 | 2005-12-29 | Merck Patent Gmbh | 3-Aminoindazole |
| DE102005035741A1 (de) * | 2005-07-29 | 2007-02-08 | Merck Patent Gmbh | Quadratsäurederivate |
| CA2644910C (en) | 2006-03-31 | 2014-01-28 | Abbott Laboratories | Indazole compounds |
| WO2007121963A1 (en) * | 2006-04-25 | 2007-11-01 | Merck Patent Gmbh | Methods for interfering with disease related to impaired mast cell activation |
| EP1980561B1 (en) | 2007-03-30 | 2013-10-09 | Nerviano Medical Sciences S.R.L. | Substituted 1h-pyrazolo[3,4-b] pyridine derivatives active as kinase inhibitors |
| TW200922558A (en) * | 2007-09-28 | 2009-06-01 | Mitsubishi Tanabe Pharma Corp | Indazole acrylic and amide compound |
| EP2412711A1 (en) * | 2009-03-27 | 2012-02-01 | Mitsubishi Tanabe Pharma Corporation | Indazolepropionic acid amide compound |
| JP2013216579A (ja) * | 2010-07-06 | 2013-10-24 | Mitsubishi Tanabe Pharma Corp | 三置換インダゾールアクリル酸アミド誘導体の製造方法 |
| US10280164B2 (en) | 2016-09-09 | 2019-05-07 | Incyte Corporation | Pyrazolopyridone compounds and uses thereof |
| WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
| CN115819417A (zh) | 2016-09-09 | 2023-03-21 | 因赛特公司 | 作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途 |
| US20180072741A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
| WO2018152220A1 (en) | 2017-02-15 | 2018-08-23 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
| US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| EP3755703B1 (en) | 2018-02-20 | 2022-05-04 | Incyte Corporation | N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer |
| US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| WO2020068729A1 (en) | 2018-09-25 | 2020-04-02 | Incyte Corporation | Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators |
| BR112022002059A2 (pt) | 2019-08-06 | 2022-06-07 | Incyte Corp | Formas sólidas de um inibidor de hpk1 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9716101D0 (en) * | 1997-07-30 | 1997-10-01 | Pharmacia & Upjohn Spa | Fused heterocyclic compounds |
| US6001865A (en) * | 1999-05-04 | 1999-12-14 | Angelini Pharmaceuticals Inc. | 3-substituted 1-benzyl-1H-indazole derivatives as antifertility agents |
-
2004
- 2004-07-23 JP JP2006521933A patent/JP2007500700A/ja active Pending
- 2004-07-23 WO PCT/US2004/023680 patent/WO2005011681A1/en not_active Ceased
- 2004-07-23 US US10/566,040 patent/US20080058515A1/en not_active Abandoned
- 2004-07-23 EP EP04778961A patent/EP1648448A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007500700A5 (https=) | ||
| ES2534392T3 (es) | Inhibidores de la proteína tirosina fosfatasa humana y métodos de uso | |
| RU2435757C2 (ru) | Производные 3-циклил-2-(4-сульфамоилфенил)-n-циклилпропионамида, применимые для лечения нарушенной переносимости глюкозы и диабета | |
| ES2846154T3 (es) | Inhibidores de la proteína tirosina fosfatasa humana y métodos de uso | |
| RU2001132139A (ru) | Имидазохинолины с сульфонамидными или сульфамидным замещением | |
| RU2001132570A (ru) | Мочевинозамещенные имидазохинолины | |
| JP2002540204A5 (https=) | ||
| RU2004104625A (ru) | Аналоги простагландинов в качестве агонистов рецептора ep4 | |
| JP2004504404A5 (https=) | ||
| JP2005526723A5 (https=) | ||
| JP2005511745A5 (https=) | ||
| JP2006515838A5 (https=) | ||
| JP2006517572A5 (https=) | ||
| JP2005524609A5 (https=) | ||
| JP2005522438A5 (https=) | ||
| CN1711085A (zh) | 含乙酸酰基苯胺衍生物作为活性成分的膀胱活动过度的治疗药物 | |
| RU2261860C2 (ru) | ЗАМЕЩЕННЫЕ В ПОЛОЖЕНИИ 8А ПРОИЗВОДНЫЕ 8,8А-ДИГИДРОИНДЕНО [1,2-d] ТИАЗОЛА, СПОСОБ ИХ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ СРЕДСТВ, НАПРИМЕР В КАЧЕСТВЕ АНОРЕКСИЧЕСКИХ СРЕДСТВ | |
| RU2008100606A (ru) | Ингибиторы сфингозинкиназы | |
| JP2008513499A5 (https=) | ||
| JP2010513434A5 (https=) | ||
| JP2004517099A5 (https=) | ||
| US8426405B2 (en) | Thiazopyrimidinones and uses thereof | |
| JP2005532331A5 (https=) | ||
| JP2007515476A5 (https=) | ||
| JP2006516626A5 (https=) |